Michelle A. Malcolmson, M.D

GigaGen, a subsidiary of Grifols, is a biotechnology company headquartered in San Carlos, California. They are focused on advancing the next generation of antibody drugs for immune deficiency, infectious diseases, and checkpoint resistant cancers. GigaGen utilizes industry-leading, single-cell technologies to recreate complete immune repertoires and discover exceptional antibodies with unique properties, enabling the development of novel mono- and polyclonal antibody drugs for a wide range of diseases. With their proprietary technology platforms, GigaGen captures and recreates complete immune repertoires as functional antibody libraries, allowing for the creation of first-in-class recombinant polyclonal antibody therapies for infectious diseases. They are also leveraging their technology for the discovery of novel recombinant polyclonal drugs and monoclonal antibodies to treat life-threatening diseases. GigaGen's lead oncology asset, GIGA-564, is an anti-CTLA-4 monoclonal antibody that has demonstrated improved anti-tumor efficacy through a unique mechanism of action.Generated from the website